Current status of antibody therapy in ALL

British Journal of Haematology

Volumn 168, Issue 4, 2015, Pages 471-480

  Ai, Jing ^a   Advani, Anjali ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukaemia; Antibody therapy; Minimal residual disease

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ANTINEOPLASTIC AGENT; BI SPECIFIC T CELL ENGAGING SPECIFIC ANTIBODY; BL 22; BLINATUMOMAB; CD19 ANTIGEN; CD20 ANTIBODY; CD22 ANTIBODY; CD52 ANTIGEN; CELL ANTIBODY; COLTUXIMAB RAVTANSINE; COMBOTOX; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; OFATUMUMAB; RITUXIMAB; SGN CD19A; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CANCER ANTIBODY; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; GENE EXPRESSION REGULATION; HUMAN; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME; TREATMENT INDICATION; ADULT; ANTIBODY SPECIFICITY; CHILD; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE; MOLECULARLY TARGETED THERAPY; PASSIVE IMMUNIZATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; LYMPHOCYTES; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION;

EID: 84922961118     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13205     Document Type: Review

References (73)

1. Advani, A.S. (2013) New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Hematology/The Education Program of the American Society of Hematology American Society of Hematology Education Program, 2013, 131-137.
2. Advani, A., Gundacker, H., Sala-Torra, O., Radich, J., Lai, R., Slovak, M.L., Lancet, J.E., Coutre, S., Stuart, R.K., Mims, M.P., Stiff, P. & Appelbaum, F.R. (2009) Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine/cytarabine for relapsed refractory acute lymphocytic leukemia. Blood, 114, 1203.
3. Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G.H., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085-2093.
4. Advani, A.S., McDonough, S., Coutre, S., Wood, B., Radich, J., Mims, M., O'Donnell, M., Elkins, S., Becker, M., Othus, M. & Appelbaum, F.R. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 165, 504-509.
5. Angiolillo, A.L., Yu, A.L., Reaman, G., Ingle, A.M., Secola, R. & Adamson, P.C. (2009) A phase II study of campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group Report. Pediatric Blood & Cancer, 53, 978-983.
6. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmuller, G., Reinhardt, C., Baeuerle, P.A. & Kufer, P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 321, 974-977.
7. Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R.J. & Lambert, J.M. (2011) SAR3419: an anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clinical Cancer Research, 17, 6448-6458.
8. Borate, U., Fathi, A.T., Shah, B.D., DeAngelo, D.J., Silverman, L.B., Cooper, T.M., Albertson, T.M., O'Meara, M.M., Sandalic, L., Stevison, F. & Chen, R. (2013) A first-in-human phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood, 122, Abstract 1437.
9. Brandl, C., Haas, C., d'Argouges, S., Fisch, T., Kufer, P., Brischwein, K., Prang, N., Bargou, R., Suzich, J., Baeuerle, P.A. & Hofmeister, R. (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunology, Immunotherapy, 56, 1551-1563.
10. Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S.A., Kiener, P., Kufer, P., Schlereth, B. & Baeuerle, P.A. (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. Journal of Immunotherapy, 30, 798-807.
11. Bruggemann, M., Raff, T., Flohr, T., Gokbuget, N., Nakao, M., Droese, J., Luschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H.A., Thiel, E., Hoelzer, D., Bartram, C.R. & Kneba, M. (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107, 1116-1123.
12. Carol, H., Szymanska, B., Evans, K., Boehm, I., Houghton, P.J., Smith, M.A. & Lock, R.B. (2013) The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clinical Cancer Research, 19, 1795-1805.
13. Chevallier, P., Bodet-Milin, C., Robillard, N., Eugene, T., Menard, A., Le Houerou, C., Guillaume, T., Delaunay, J., Escoffre-Barbe, M., Wegener, W.A., Goldenberg, D.M. & Kraeber-Bodere, F. (2013) BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. European Journal of Haematology, 91, 552-556.
14. Cruz, R.I., Hernandez-Ilizaliturri, F.J., Olejniczak, S., Deeb, G., Knight, J., Wallace, P., Thurberg, B.L., Kennedy, W. & Czuczman, M.S. (2007) CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia & Lymphoma, 48, 2424-2436.
15. DeAngelo, D., Stock, W., Petersdorf, S., Wang, S.L., Volkert, A., Vandendries, E. & Advani, A. (2012) Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), 120, 2612.
16. DeAngelo, D., Stock, W., Shustov, A., Liedtke, M., Schiffer, C., Ananthakrishnan, R., Boni, J., Luu, K., Liau, K., Vandendries, E. & Advani, A. (2013) Weekly inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 122, 3906.
17. DiJoseph, J.F., Dougher, M.M., Armellino, D.C., Evans, D.Y. & Damle, N.K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia, 21, 2240-2245.
18. Dworzak, M.N., Schumich, A., Printz, D., Potschger, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G. & Gadner, H. (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 112, 3982-3988.
19. Fielding, A.K., Richards, S.M., Chopra, R., Lazarus, H.M., Litzow, M.R., Buck, G., Durrant, I.J., Luger, S.M., Marks, D.I., Franklin, I.M., McMillan, A.K., Tallman, M.S., Rowe, J.M., Goldstone, A.H., Medical Research Council of the United Kingdom Adult, A.L.L.W.P. & Eastern Cooperative Oncology, G. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 109, 944-950.
20. Gaynon, P.S., Harris, R.E., Altman, A.J., Bostrom, B.C., Breneman, J.C., Hawks, R., Steele, D., Zipf, T., Stram, D.O., Villaluna, D. & Trigg, M.E. (2006) Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. Journal of Clinical Oncology, 24, 3150-3156.
21. Giles, F.J., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garcia-Manero, G., Waddelow, T.A., David, C.L., Phan, A.T., Colburn, D.E., Rashid, A. & Estey, E.H. (2001) Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413.
22. Handgretinger, R., Zugmaier, G., Henze, G., Kreyenberg, H., Lang, P. & von Stackelberg, A. (2011) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia, 25, 181-184.
23. Herrera, L., Bostrom, B., Gore, L., Sandler, E., Lew, G., Schlegel, P.G., Aquino, V., Ghetie, V., Vitetta, E.S. & Schindler, J. (2009) A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology, 31, 936-941.
24. Hoelzer, D., Goekbuget, N., Beck, J., Burmeister, T., Giagounidis, A., Glasmacher, A., Pfeifer, H., Rieder, H., Schmid, M., Thiel, E., Wassmann, B. & Ottmann, O. (2004) Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL). Blood, 104, 747a.
25. Hoelzer, D., Huettmann, A., Kaul, F., Irmer, S., Jaekel, N., Mohren, M., Lipp, T., Wedelin, K., de Valle, F., Schmid, M., Thiel, E., Brueggemann, M., Kneba, M. & Goekbuget, N. (2010) Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood, 116, 77-78.
26. Hu, Y.P., Turner, M.J., Shields, J., Gale, M.S., Hutto, E., Roberts, B.L., Siders, W.M. & Kaplan, J.M. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology, 128, 260-270.
27. Jabbour, E., Kantarjian, H., Thomas, D., Garcia-Manero, G., Hoehn, D., Garris, R., Faderl, S., Cortes, J., Kadia, T., Ravandi, F., Verstovsek, F. & O'Brien, S. (2013) Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 122, 2664.
28. Jain, N., O'Brien, S., Thomas, D., Jabbour, E., Faderl, F., Ravandi, F., Borthakur, G., York, S., Garris, R., Cortes, J. & Kantarjian, H. (2013) Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients (≥60 years) with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 122, 1432.
29. Jazirehi, A.R., Vega, M.I. & Bonavida, B. (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Research, 67, 1270-1281.
30. Kantarjian, H., Thomas, D., Wayne, A.S. & O'Brien, S. (2012a) Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. Journal of Clinical Oncology, 30, 3876-3883.
31. Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., Rios, M.B., Cortes, J., Fayad, L., Tarnai, R., Wang, S.A., Champlin, R., Advani, A. & O'Brien, S. (2012b) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet. Oncology, 13, 403-411.
32. Kreitman, R.J. & Pastan, I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clinical Cancer Research, 17, 6398-6405.
33. Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., van Dongen, J.J.M., Bernstein, I.D., Appelbaum, F.R. & Grp, M.S. (2001) Update of efficacy and safety of gemtuzumab ozogamicin (Mylotarg (R), CMA-676) in patients >=60 years of age with acute myeloid leukemia in first relapse. Blood, 98, 215b.
34. Li, B., Zhao, L., Guo, H., Wang, C., Zhang, X., Wu, L., Chen, L., Tong, Q., Qian, W., Wang, H. & Guo, Y. (2009) Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood, 114, 5007-5015.
35. Litzow, M.R. (2011) Novel therapeutic approaches for acute lymphoblastic leukemia. Hematology/Oncology Clinics of North America, 25, 1303-1317.
36. Liu, X.Y., Pop, L.M., Schindler, J. & Vitetta, E.S. (2012) Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. MAbs, 4, 57-68.
37. Moorman, A.V., Harrison, C.J., Buck, G.A.N., Richards, S.M., Secker-Walker, L.M., Martineau, M., Vance, G.H., Cherry, A.M., Higgins, R.R., Fielding, A.K., Foroni, L., Paietta, E., Tallman, M.S., Litzow, M.R., Wiernik, P.H., Rowe, J.M., Goldstone, A.H. & Dewald, G.W. (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 109, 3189-3197.
38. Mussai, F., Campana, D., Bhojwani, D., Stetler-Stevenson, M., Steinberg, S.M., Wayne, A.S. & Pastan, I. (2010) Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 150, 352-358.
39. Nagorsen, D. & Baeuerle, P.A. (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experimental Cell Research, 317, 1255-1260.
40. Nagorsen, D., Bargou, R., Ruttinger, D., Kufer, P., Baeuerle, P.A. & Zugmaier, G. (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leukemia & Lymphoma, 50, 886-891.
41. Obrien, S., Thomas, D., Jorgensen, J., Kebriaei, P., Ravandi, F., Kwari, M., Faderl, S., Cortes, J., Jabbour, E., York, S., Garris, R. & Kantarjian, H. (2012) Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 120, 671.
42. Pagano, L., Mele, L., Trape, G. & Leone, G. (2004) The treatment of acute lymphoblastic leukaemia in the elderly. Leukemia & Lymphoma, 45, 117-123.
43. Paietta, E., Li, X.C., Richards, S., Racevskis, J., Dewald, G.W., Rowe, J.M., Tallman, M.S., Lazarus, H.M., Litzow, M., Goldstone, A.H. & Wiernik, P.H. (2008) Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-lineage (B-Lin) ALL patients (pts) on the MRC UKALLXII/ECOG2993 intergroup trial. Blood, 112, 666-667.
44. Poe, J.C., Fujimoto, Y., Hasegawa, M., Haas, K.M., Miller, A.S., Sanford, I.G., Bock, C.B., Fujimoto, M. & Tedder, T.F. (2004) CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nature Immunology, 5, 1078-1087.
45. Polson, A.G., Ho, W.Y. & Ramakrishnan, V. (2011) Investigational antibody-drug conjugates for hematological malignancies. Expert Opinion on Investigational Drugs, 20, 75-85.
46. Portell, C.A. & Advani, A.S. (2012) Antibody therapy for acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 7, 153-159.
47. Portell, C.A. & Advani, A.S. (2014) Novel targeted therapies in acute lymphoblastic leukemia. Leukemia & Lymphoma, 55, 737-748.
48. Raetz, E.A., Cairo, M.S., Borowitz, M.J., Blaney, S.M., Krailo, M.D., Leil, T.A., Reid, J.M., Goldenberg, D.M., Wegener, W.A., Carroll, W.L. & Adamson, P.C. (2008a) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study. Journal of Clinical Oncology, 26, 3756-3762.
49. Raetz, E.A., Borowitz, M.J., Devidas, M., Linda, S.B., Hunger, S.P., Winick, N.J., Camitta, B.M., Gaynon, P.S. & Carroll, W.L. (2008b) Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. Journal of Clinical Oncology, 26, 3971-3978.
50. Raetz, E.A., Cairo, M.S., Borowitz, M.J., Lu, X.M., Devidas, M., Reid, J.M., Goldenberg, D.M., Wegener, W.A., Whitlock, J.A., Adamson, P.C., Hunger, S.P. & Carroll, W.L. (2011) Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children's Oncology Group (COG) Study ADVL04P2. Blood, 118, 264.
51. Raponi, S., De Propris, M.S., Intoppa, S., Milani, M.L., Vitale, A., Elia, L., Perbellini, O., Pizzolo, G., Foa, R. & Guarini, A. (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leukemia & Lymphoma, 52, 1098-1107.
52. Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Laine, F., Houot, R., Haioun, C., Copie, C., Varga, A., Lambert, J., Hatteville, L., Ziti-Ljajic, S., Caron, A., Payrard, S. & Coiffier, B. (2014) A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 20, 213-220.
53. Rizzieri, D.A., Johnson, J.L., Byrd, J.C., Lozanski, G., Powell, B.L., Shea, T.C., Nattom, S., Hoke, E., Cheson, B.D. & Larson, R. (2010) Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt - like leukemia/lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002. Blood, 116, 374-375.
54. Rowe, J.M., Buck, G., Burnett, A.K., Chopra, R., Wiernik, P.H., Richards, S.M., Lazarus, H.M., Franklin, I.M., Litzow, M.R., Ciobanu, N., Prentice, H.G., Durrant, J., Tallman, M.S. & Goldstone, A.H. (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 106, 3760-3767.
55. Salvatore, G., Beers, R., Margulies, I., Kreitman, R.J. & Pastan, I. (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clinical Cancer Research, 8, 995-1002.
56. Schindler, J., Gajavelli, S., Ravandi, F., Shen, Y., Parekh, S., Braunchweig, I., Barta, S., Ghetie, V., Vitetta, E. & Verma, A. (2011) A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 154, 471-476.
57. Silverman, L.B., Gelber, R.D., Dalton, V.K., Asselin, B.L., Barr, R.D., Clavell, L.A., Hurwitz, C.A., Moghrabi, A., Samson, Y., Schorin, M.A., Arkin, S., Declerck, L., Cohen, H.J. & Sallan, S.E. (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, 97, 1211-1218.
58. Stock, W., Sanford, B., Lozanski, G., Vij, R., Byrd, J.C., Powell, B.L., Wetzler, M., Sher, D., Edwards, C., Kelly, M., Richards, S., Sung, C., Malnassy, G., Hoke, E., Bloomfield, C.D. & Larson, R.A. (2009) Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood, 114, 345.
59. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. & van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology, 177, 362-371.
60. Thomas, D.A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J.Q., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
61. Thomas, D.A., O'Brien, S., Jorgensen, J.L., Cortes, J., Faderl, S., Garcia-Manero, G., Verstovsek, S., Koller, C., Pierce, S., Huh, Y., Wierda, W., Keating, M.J. & Kantarjian, H.M. (2009a) Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood, 113, 6330-6337.
62. Thomas, D.A., O'Brien, S. & Kantarjian, H.M. (2009b) Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematology/Oncology Clinics of North America, 23, 949-971.
63. Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J.L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M.J., Cortes, J. & Kantarjian, H.M. (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 28, 3880-3889.
64. Tibes, R., Keating, M.J., Ferrajoli, A., Wierda, W., Ravandi, F., Garcia-Manero, G., O'Brien, S., Cortes, J., Verstovsek, S., Browning, M.L. & Faderl, S. (2006) Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer, 106, 2645-2651.
65. Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Kohne-Volland, R., Bruggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P.A., Kneba, M., Einsele, H., Riethmuller, G., Hoelzer, D., Zugmaier, G. & Bargou, R.C. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29, 2493-2498.
66. Topp, M.S., Gokbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.E., Klinger, M., Neumann, S.A., Horst, H.A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Kohne-Volland, R., Bruggemann, M., Ottmann, O.G., Burmeister, T., Baeuerle, P.A., Nagorsen, D., Schmidt, M., Einsele, H., Riethmuller, G., Kneba, M., Hoelzer, D., Kufer, P. & Bargou, R.C. (2012a) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood, 120, 5185-5187.
67. Topp, M., Goekbuget, N., Zugmaier, G., Viardot, A., Stelljes, M., Neumann, S., Horst, H.A., Reichle, A., Marks, R., Monika, B., Ritgen, M., Klappers, P., Mergen, N., Goebeler, M.E., Einsele, H., Hoelzer, D. & Bargou, R. (2012b) Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. Journal of Clinical Oncology, 30, 6500.
68. de Vries, J.F., Zwaan, C.M., De Bie, M., Voerman, J.S.A., den Boer, M.L., van Dongen, J.J.M. & van der Velden, V.H.J. (2012) The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia, 26, 255-264.
69. Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., Alyea, E.P., Antin, J.H., Stone, R.M., Soiffer, R.J. & DeAngelo, D.J. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, 1578-1582.
70. Watanabe, T., Masuyama, J., Sohma, Y., Inazawa, H., Horie, K., Kojima, K., Uemura, Y., Aoki, Y., Kaga, S., Minota, S., Tanaka, T., Yamaguchi, Y., Kobayashi, T. & Serizawa, I. (2006) CD52 is a novel costimulatory molecule for induction of CD4(+) regulatory T cells. Clinical Immunology, 120, 247-259.
71. Wayne, A.S., Kreitman, R.J., Findley, H.W., Lew, G., Delbrook, C., Steinberg, S.M., Stetler-Stevenson, M., Fitzgerald, D.J. & Pastan, I. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16, 1894-1903.
72. Wayne, A.S., Bhojwani, D., Silverman, L.B., Richards, K., Stetler-Stevenson, M., Shah, N.N., Jeha, S., Pui, C.H., Buzoianu, M., FitzGerald, D.J., Kreitman, R.J., Ibrahim, R. & Pastan, I. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood, 118, 113.
73. Wei, H., Xiang, L., Wayne, A.S., Chertov, O., FitzGerald, D.J., Bera, T.K. & Pastan, I. (2012) Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proceedings of the National Academy of Sciences of the United States of America, 109, 6898-6903.